EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study

Medikamentöse Behandlungen nach 6 Monaten bei hospitalisierten und ambulanten HFrEF-Patient:innen in der BRING-UP 3 Heart Failure-Studie

Fabrizio Oliva iD, Francesco Orso iD, Furio Colivicchi, Manlio Gianni Cipriani, Andrea Di Lenarda iD, Mauro Gori iD, Marco Gorini, Massimo Iacoviello iD, Donata Lucci, Marco Marini, Eleonora Bonvicini, Stefano Carugo und 12 weitere

ESC Heart Failure · 03.03.2026 · 13 (2)

DOI: 10.1093/eschf/xvag043 ↗

Auf einen Blick

In einer prospektiven Kohorte von HFrEF-Patient:innen blieben GDMT-Verordnungen über 6 Monate insgesamt stabil. Quadruple therapy mit ARNI nahm leicht zu, die Dosistitration blieb jedoch gering.

Fragestellung

Wie häufig werden die vier GDMT-Bausteine bei HFrEF-Patient:innen nach 6 Monaten in der klinischen Praxis eingesetzt?

Methode

Prospektive, beobachtende, landesweite Studie an 179 Zentren; Analyse von ambulanten und hospitalisierten HFrEF-Patient:innen mit vollständigen Pharmadaten nach 6 Monaten.

Ergebnisse

3201 eingeschlossene HFrEF-Patient:innen; 142 (4,4 %) waren bis 6 Monate verstorben, 2950 hatten Behandlungsdaten. Quadruple therapy: 64,3 % vs. 63,9 % zu Baseline/Entlassung; mit ARNI: 52,9 % vs. 55,9 % (P < .0001).

Schlussfolgerung der Autor:innen

In dieser großen landesweiten Kohorte wurden leitliniengerechte Therapien bei HFrEF breit umgesetzt und über 6 Monate beibehalten; die Optimierung der Dosis bleibt ein wichtiges unerfülltes Bedürfnis.

Kernaussagen

  • GDMT blieb über 6 Monate insgesamt stabil
  • Quadruple therapy: 64,3 % nach 6 Monaten
  • Dosissteigerungen blieben meist unter 50 % der Zieldosis

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, online erschienen am 31.01.2026. Verfasst von Fabrizio Oliva und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Niguarda Hospital, Milano, Italy. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Hospitalization, Ambulatory Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Heart Care Foundation, Boehringer-Ingelheim Italia, Eli-Lilly Italia.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The BRING-UP 3 Heart Failure (HF) study was designed to evaluate the real-world implementation of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF), given the limited evidence on the uptake of the contemporary four-pillar treatment strategy.

Methods

BRING-UP 3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites. This analysis includes HFrEF patients enrolled in the ambulatory and hospitalized cohorts with complete pharmacological data at 6-month follow-up. The objective was to describe the use of the four GDMT pillars after 6 months.

Results

Among 3201 HFrEF patients enrolled, 142 (4.4%) had died by 6 months, and treatment data were available for 2950 patients. Mean age was 69 ± 11 years (26.6% > 75 years), 18.0% were female. Prescription rates of GDMT were high at baseline and remained stable over 6-months, with a shift from ACE-I/ARBs to ARNIs, and a modest increase in SGLT2i use. A significant reduction in diuretic prescription was also observed. Quadruple therapy was prescribed in 64.3% of patients at 6 months versus 63.9% at baseline/discharge (P = NS), while quadruple therapy including ARNI went from 52.9% to 55.9%, P < .0001. Dose up-titration of GDMT remained suboptimal, with most agents prescribed at <50% of target doses. Discontinuation rates at follow-up were very low.

Conclusion

In this large nationwide cohort, guideline-directed therapies for HFrEF were widely implemented and maintained over 6 months with excellent treatment persistence. However, dose optimization remains a key unmet need in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeHospitalizationAmbulatory CareAngiotensin-Converting Enzyme InhibitorsHumansFemaleMaleProspective StudiesAgedFollow-Up StudiesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

AdherenceChronic heart failureGuidelinesMedical treatmentsRegistry

Substanzen

Angiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Cardiology Unit, Niguarda Hospital, Milano, Italy.
  • ANMCO Research Center, Heart Care Foundation, Via La Marmora 36, 50121 Firenze, Italy.
  • Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Roma, Italy.
  • Clinical Cardiology and Heart Failure Unit, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT) - IRCCS, Palermo, Italy.
  • Cardiovascular Center, University Hospital and Health Services of Trieste, Trieste, Italy.
  • Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.

ORCID-Profile: Fabrizio Oliva, Francesco Orso, Andrea Di Lenarda, Mauro Gori, Massimo Iacoviello, Emilia D'Elia, Alessandro Navazio, Massimo Grimaldi, Domenico Gabrielli, Aldo Pietro Maggioni

Förderung

  • Heart Care Foundation
  • Boehringer-Ingelheim Italia
  • Eli-Lilly Italia
  • Novartis Farma SpA
  • Vifor Pharma Italia

Zitieren

APA

Oliva, F., Orso, F., Colivicchi, F., Cipriani, M. G., Di Lenarda, A., Gori, M., Gorini, M., Iacoviello, M., Lucci, D., Marini, M., Bonvicini, E., Carugo, S., Catalano, M., D'Elia, E., Gentile, P., Matassini, M. V., Navazio, A., Russo, D., Tini, G., …, & BRING-UP 3 Heart Failure Investigators (2026). Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study. ESC Heart Failure, 13(2). https://doi.org/10.1093/eschf/xvag043

Vancouver

Oliva F, Orso F, Colivicchi F, Cipriani MG, Di Lenarda A, Gori M, et al. Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study. ESC Heart Failure. 2026;13(2). doi:10.1093/eschf/xvag043

BibTeX
@article{Oliva2026,
  author = {Oliva, Fabrizio and Orso, Francesco and Colivicchi, Furio and Cipriani, Manlio Gianni and Di Lenarda, Andrea and Gori, Mauro and Gorini, Marco and Iacoviello, Massimo and Lucci, Donata and Marini, Marco and Bonvicini, Eleonora and Carugo, Stefano and Catalano, Mariarosaria and D'Elia, Emilia and Gentile, Piero and Matassini, Maria Vittoria and Navazio, Alessandro and Russo, Domitilla and Tini, Giacomo and Tinti, Maria Denitza and Grimaldi, Massimo and Gabrielli, Domenico and Maggioni, Aldo Pietro and BRING-UP 3 Heart Failure Investigators, BRING-UP 3 Heart Failure Investigators},
  title = {Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {2},
  doi = {10.1093/eschf/xvag043}
}
Kostenlos starten →